In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats

Biotechnology Journal

Volumn 5, Issue 3, 2010, Pages 321-327

  Barth, Stephan W ^a   Briviba, Karlis ^a   Watzl, Bernhard ^a   Jäger, Nicole ^b   Marko, Doris ^b,c   Esselen, Melanie ^b,d  

^a FEDERAL RESEARCH INSTITUTE OF NUTRITION AND FOOD   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF VIENNA   (Austria)

^d Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

Author keywords

Cleavable complex; Comet assay; DNA strand breaks; Methods; Topoisomerase poison

Indexed keywords

ANTI-CANCER AGENTS; BODY WEIGHT; COLON TISSUES; COMET ASSAYS; CONTROL GROUPS; COVALENTLY BOUND; DISTAL COLONS; DNA DAMAGES; DNA INTEGRITY; DNA STRAND BREAK; DNA STRANDS; IN-VIVO; INTRAPERITONEALLY; IRINOTECAN; SINGLE-CELL GEL ELECTROPHORESIS; SINGLE-DOSE; TEST SYSTEMS; TOPOISOMERASE I; TOPOISOMERASE I POISONS; TOPOISOMERASE POISON; TOPOISOMERASES; WISTAR RAT;

DNA; ELECTROPHORESIS; GENES; LIVER; RATS; SODIUM; SODIUM CHLORIDE;

BIOASSAY;

DNA TOPOISOMERASE; IRINOTECAN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; BODY WEIGHT; COLON MUCOSA; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; DUODENUM MUCOSA; IN VIVO COMPLEXES OF ENZYME TO DNA BIOASSAY; LIVER; MALE; MUCOSA CELL; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; STOMACH MUCOSA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COMET ASSAY; DNA; DNA BREAKS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; ENZYME INHIBITORS; GASTROINTESTINAL TRACT; LIVER; MACROMOLECULAR SUBSTANCES; MALE; PILOT PROJECTS; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS;

RATTUS; RATTUS NORVEGICUS;

EID: 77949460003     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.200900174     Document Type: Article

References (31)

1. Mathijssen, R. H., Loos, W. J., Verweij, J., Sparreboom, A., Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr. Cancer Drug Targets 2002, 2, 103-123.
2. Garcia-Carbonero, R., Supko, J. G., Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 2002, 8, 641-661.
3. Xie, R., Mathijssen, R. H., Sparreboom, A.,Verweij, J. et al., Clinical pharmacokinetics of irinotecan and its metabolites: A population analysis. J. Clin. Oncol. 2002, 20, 3293-3301.
4. Pommier,Y.,Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer 2006, 6, 789-802.
5. Satoh,T., Hosokawa, M., Atsumi, R., Suzuki,W. et al., Metabolic activation of CPT-11,7-ethyl-10-[4-(1-piperidino)-1piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm. Bull. 1994, 17, 662-664.
6. Kaufmann, S. H., Charron, M., Burke, P. J., Karp, J. E., Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo. Cancer Res. 1995, 55, 1255-1260.
7. Husain, I., Mohler, J. L., Seigler, H. F., Besterman, J. M., Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumortype specificity and implications for cancer chemotherapy. Cancer Res. 1994, 54, 539-546.
8. McLeod HL, Douglas F, Oates M, Symonds,R. P. et al.,Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int. J. Cancer 1994, 59, 607-611.
9. Hsiang, Y. H., Liu, L. F., Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988, 48, 1722-1726.
10. Champoux, J. J., DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem. 2001, 70, 369-413.
11. Subramanian, D., Furbee, C. S., Muller, M. T., ICE-bioassay. Isolating in vivo complexes of enzyme to DNA. Methods Mol. Biol. 2001, 95, 137-147.
12. Bandele, O. J., Osheroff, N., Bioflavonoids as poisons of human topoisomerase II alpha and II beta. Biochemistry 2007, 46, 6097-6108.
13. Mao,Y., Okada,S., Chang, L.S., Muller,M.T., p53 dependence of topoisomerase I recruitment in vivo. Cancer Res. 2000, 60, 4538-4543.
14. Pobst, L. J.,Ames,M. M., CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines. Cancer Chemother. Pharmacol. 2006, 57, 569-576.
15. van Waardenburg, R. C., de Jong, L. A., van Eijndhoven, M. A., Verseyden, C. et al., Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J. Biol. Chem. 2004, 279, 54502-54509.
16. Kancherla, R. R., Nair, J.S.,Ahmed,T., Durrani, H. et al.,Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: Correlation of topoisomerase-DNA complex formation with clinical response. Cancer 2001, 91, 463-471.
17. Subramanian, D., Kraut, E., Staubus, A., Young, D. C. et al., Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res. 1995, 55, 2097-2103.
18. Pool-Zobel,B. L.,Neudecker,C., Domizlaff, I., Ji,S. et al., Lactobacillus- and bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr. Cancer 1996, 26, 365-380.
19. Desai, S. D., Li,T. K., Rodriguez-Bauman, A., Rubin, E. H. et al., Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001, 61, 5926-5932.
20. Desai, S. D., Zhang, H., Rodriguez-Bauman, A.,Yang, J. M. et al.,Transcription-dependent degradation of topoisomerase I-DNA covalent complexes. Mol. Cell. Biol. 2003, 23, 2341-2350.
21. Lin,C.P., Ban,Y.,Lyu,Y. L., Desai,S.D. et al.,A ubiquitin-proteasome pathway for the repair of topoisomerase I-DNA covalent complexes. J. Biol. Chem. 2008, 283, 21074-21083.
22. Dexheimer,T. S.,Antony, S., Marchand,C.,Pommier,Y.,Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. Anticancer Agents Med. Chem. 2008, 8, 381-389.
23. El-Khamisy, S. F., Saifi, G. M.,Weinfeld, M., Johansson, F. et al., Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 2005, 434, 108-113.
24. Araki, E., Ishikawa, M., Iigo, M., Koide,T. et al., Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J. Cancer Res. 1993, 84, 697-702.
25. Nakamura,Y., Satake, K., Sano, K., Ito,A et al., Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats. Chemotherapy 2008, 54, 485-491.
26. Esselen, M.,Fritz, J., Hutter, M., Marko,D., Delphinidin modulates the DNA-damaging properties of topoisomerase II poisons. Chem. Res.Toxicol. 2009, 22, 554-564.
27. Iyer, L., King, C. D.,Whitington, P. F., Green, M. D. et al., Genetic predisposition to the metabolism of irinotecan (CPT-11). J. Clin. Invest. 1998, 101, 847-854.
28. Godard,T., Fessard,V., Huet, S., Mourot, A. et al., Comparative in vitro and in vivo assessment of genotoxic effects of etoposide and chlorothalonil by the comet assay. Mutat. Res. 1999, 444, 103-116.
29. Gibson, R. J.,Bowen, J. M., Inglis,M. R., Cummins,A.G. et al., Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J. Gastroenterol. Hepatol. 2003, 18, 1095-1100.
30. Lin, L. C.,Wang, M. N., Tsai, T. H., Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38. Chem. Biol. Interact. 2008, 174, 177-182.
31. Bowen, J. M., Stringer, A. M., Gibson, R. J., Yeoh, A. S. et al., VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol. Ther. 2007, 6, 1449-1454.